Literature DB >> 2316941

Endoscopic retrograde cholangiopancreatography in a general surgery practice.

D E Scheeres1, I Simon, J L Ponsky.   

Abstract

Endoscopic retrograde cholangiopancreatography (ERCP) is performed for the diagnosis and therapy of benign and malignant biliary and pancreatic disease. There are few reports in the literature regarding the incorporation of this procedure into a general surgery practice. One hundred seven consecutive ERCPs performed by the same surgeon over a two-year period were reviewed. The most frequent indications for ERCP were jaundice, suspected common bile duct stones, and a history of pancreatitis. Successful cannulation of the ampulla of Vater was achieved in 97 per cent of the cases with the desired duct being adequately visualized in 90 per cent of the cases. Sphincterotomy was performed in 42 per cent of the procedures and common bile duct stones were removed with a balloon or basket catheter. The overall complication rate was seven per cent with no mortality. ERCP accounted for 20 per cent of all endoscopies and 12 per cent of all procedures performed by the surgeon. Twelve per cent of these patients were subsequently operated upon by the surgeon while another 16 per cent requiring surgery were returned to the referring physician. This study supports the feasibility of the incorporation of ERCP into a general surgery practice.

Entities:  

Mesh:

Year:  1990        PMID: 2316941

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Complications of endoscopic retrograde cholangiography in the post-MRCP era: a tertiary center experience.

Authors:  Tze-Zen Ong; Jen-Lock Khor; Dede-Sutedja Selamat; Khay-Guan Yeoh; Khek-Yu Ho
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

2.  Pediatric ERCP in a multidisciplinary community setting: experience with a fellowship-trained general surgeon.

Authors:  J A Green; D E Scheeres; H A Conrad; D L Cloney; M G Schlatter
Journal:  Surg Endosc       Date:  2007-05-19       Impact factor: 4.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.